BioSpace News Archive

Liminal BioSciences Inc. today announced that the first subject has been dosed in the Company’s Phase 1a single ascending dose randomized, open label, cross over clinical trial of fezagepras.

Amyris, Inc. announced that management will participate in fireside chats at the following upcoming investor conferences.

Element Biosciences Inc. , developer of the Element AVITI™ System, a new and disruptive DNA sequencing platform, today announced the appointment of Mark Aitkenhead, PhD, as Chief Commercial Officer.

The Family Heart Foundation, a leading research and advocacy organization, today announced study results that demonstrate individuals with elevated lipoprotein(a) – also referred to as Lp(a) —levels experience an increased rate of cardiovascular events.

Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal.

Thermo Fisher Scientific, the world leader in serving science, and Qatar Genome Program (QGP), a member of Qatar Foundation (QF), have partnered with the goal of accelerating genomic research and clinical applications of predictive genomics in Qatar as a as a step toward expanding the benefits of precision medicine across Arab populations globally.

Edwards Lifesciences Corporation (NYSE: EW) today announced it is scheduled to present at the Bernstein 38th Annual Strategic Decisions Conference on Thursday, June 2 , 2022.

CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that results from new analyses of clinical studies of seladelpar were presented during Digestive Disease Week® (DDW) .

RAPT Therapeutics, Inc. (Nasdaq: RAPT), today announced it has initiated its 16-week randomized, double-blind, placebo-controlled Phase 2b clinical trial to further evaluate the efficacy and safety of RPT193 as monotherapy in patients with moderate-to-severe atopic dermatitis (AD).

Ascendis Pharma A/S (Nasdaq: ASND) announced today that results from VISEN Pharmaceuticals’ Phase 3 trial of once-weekly TransCon hGH in children with GHD in China demonstrated results that were consistent with the Ascendis Pharma’s earlier multi-national Phase 3 trial.